Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

S. Tolaney · SciRah

Researcher profile · Semantic Scholar

S. Tolaney

Share profile

S. Tolaney — researcher profile on SciRah

h-index: 77
Works: 771
Citations: 26K

Most-cited papers

Sacituzumab govitecan (SG) + pembrolizumab (pembro) vs chemotherapy (chemo) + pembro in previously untreated PD-L1–positive advanced triple-negative breast cancer (TNBC): Primary results from the randomized phase 3 ASCENT-04/KEYNOTE-D19 study.
S. Tolaney, E. de Azambuja, K. Kalinsky, S. Loi +16 more
2025Journal of Clinical Oncology64 citations Open access
Semantic Scholar
Trastuzumab deruxtecan (T-DXd) + pertuzumab (P) vs taxane + trastuzumab + pertuzumab (THP) for first-line (1L) treatment of patients (pts) with human epidermal growth factor receptor 2–positive (HER2+) advanced/metastatic breast cancer (a/mBC): Interim results from DESTINY-Breast09.
S. Tolaney, Ze-Fei Jiang, Qing-Yuan Zhang, R. Barroso-Sousa +15 more
2025Journal of Clinical Oncology39 citations
Semantic Scholar
The Mode of Action and Clinical Outcomes of Sacituzumab Govitecan in Solid Tumors
S. Tolaney, Thomas M Cardillo, Chih-Chien Chou, Carrie Dornan +1 more
2025Clinical Cancer Research36 citations Open access
Semantic Scholar
TROPION-Breast04: a randomized phase III study of neoadjuvant datopotamab deruxtecan (Dato-DXd) plus durvalumab followed by adjuvant durvalumab versus standard of care in patients with treatment-naïve early-stage triple negative or HR-low/HER2− breast cancer
H. McArthur, S. Tolaney, R. Dent, P. Schmid +12 more
2025Therapeutic Advances in Medical Oncology30 citations Open access
Semantic Scholar
Phase I study of ribociclib (CDK4/6 inhibitor) with spartalizumab (PD-1 inhibitor) with and without fulvestrant in metastatic hormone receptor-positive breast cancer or advanced ovarian cancer
A. Garrido-Castro, N. Graham, Lestat R. Ali, C. Herold +14 more
2025Journal for ImmunoTherapy of Cancer18 citations Open access
Semantic Scholar
Real-world risk of recurrence and treatment outcomes with adjuvant endocrine therapy in patients with stage II-III HR+/HER2- early breast cancer
J. O'Shaughnessy, S. Tolaney, D. Yardley, L. Hart +10 more
2025Breast17 citations Open access
Semantic Scholar
A phase 2 study of response-guided neoadjuvant sacituzumab govitecan and pembrolizumab (SG/P) in patients with early-stage triple-negative breast cancer: Results from the NeoSTAR trial.
R. Abelman, S. McLaughlin, Geoffrey Fell, A. Garrido-Castro +15 more
2025Journal of Clinical Oncology12 citations
Semantic Scholar
CAMBRIA-1 & CAMBRIA-2 phase III trials: camizestrant versus standard endocrine therapy in ER+/HER2– early breast cancer
E. Hamilton, S. Loibl, T. Bachelot, M. Gnant +15 more
2025Future Oncology11 citations Open access
Semantic Scholar
Prognostic and molecular multi-platform analysis of CALGB 40603 (Alliance) and public triple-negative breast cancer datasets
B. Felsheim, A. Fernández-Martínez, C. Fan, A. Pfefferle +8 more
2025npj Breast Cancer9 citations Open access
Semantic Scholar
A Phase II Study of Abemaciclib for Patients with Retinoblastoma-Positive, Metastatic Triple-Negative Breast Cancer
Shom Goel, B. Jovanović, X. Chu, M. Hughes +10 more
2025Clinical Cancer Research8 citations Open access
Semantic Scholar
Outcomes and treatment patterns for stage I human epidermal growth factor receptor 2‐positive breast cancer in the Surveillance, Epidemiology, and End Results database, 2010–2019
A. Waks, P. Tarantino, Emily L. Chen, R. Freedman +6 more
2025Cancer7 citations
Semantic Scholar
LBA18 Trastuzumab deruxtecan (T-DXd) + pertuzumab (P) vs taxane + trastuzumab + pertuzumab (THP) for patients (pts) with HER2+ advanced/metastatic breast cancer (a/mBC): Additional analyses of DESTINY-Breast09 in key subgroups of interest
S. Loibl, Z. Jiang, R. Barroso-Sousa, Y. Park +15 more
2025Annals of Oncology7 citations Open access
Semantic Scholar
Expert consensus on treating HR+/HER2- metastatic breast cancer based on real-world practice patterns observed in the RETRACT survey of US oncologists
H. Rugo, A. Bardia, W. Gradishar, E. Hamilton +4 more
2025Breast6 citations Open access
Semantic Scholar
The TRADE study: A phase 2 trial to assess the tolerability of abemaciclib dose escalation in early-stage HR+/HER2- breast cancer.
E. Mayer, D. Trapani, S. Kim, M. Faggen +16 more
2025Journal of Clinical Oncology6 citations Open access
Semantic Scholar
Abstract P1-08-08: Real-world efficacy of immediate subsequent lines of therapy after trastuzumab deruxtecan (T-DXd) in patients with metastatic breast cancer (MBC) – retrospective study from the nationwide Flatiron database
P. Tarantino, Do H. Lee, J. Foldi, P. Soulos +10 more
2025Clinical Cancer Research6 citations
Semantic Scholar
Abstract RF3-01: TBCRC 056: A Phase II Study of Neoadjuvant Niraparib with Dostarlimab for Patients with BRCA- or PALB2-mutated Breast Cancer: Results From the ER+/HER2- Cohort
E. Mayer, N. Graham, R. Leon-Ferre, M. Rozenblit +14 more
2025Clinical Cancer Research3 citations
Semantic Scholar
Abstract P5-03-11: DEMETHER: A single-arm phase II trial to evaluate the efficacy & safety of subcutaneous pertuzumab & trastuzumab maintenance after induction treatment w/ trastuzumab deruxtecan (T-DXd) for previously untreated HER2-positive advanced breast cancer
J. Cortés, J. García-Mosquera, G. Antonarelli, A. Gennari +15 more
2025Clinical Cancer Research3 citations
Semantic Scholar
Elacestrant combinations in patients (pts) with ER+/HER2- locally advanced or metastatic breast cancer (mBC): Safety update from ELEVATE, a phase (Ph) 1b/2, open-label, umbrella study.
N. Chan, V. Kaklamani, S. Tolaney, E. Hamilton +13 more
2025Journal of Clinical Oncology3 citations
Semantic Scholar
Abstract P2-07-25: Thymidine kinase activity as a prognostic and predictive biomarker in the Phase II PACE trial of CDK4/6 inhibition beyond progression
Nader-Marta, Yue Ren, R. Mahtani, Cynthia X. Ma +19 more
2025Clinical Cancer Research2 citations
Semantic Scholar
Q-TWiST Analysis of Sacituzumab Govitecan vs. Chemotherapy in Previously Treated Patients with HR+/HER2− Metastatic Breast Cancer
H. Rugo, A. Bardia, P. Schmid, S. Tolaney +7 more
2025Current Oncology2 citations Open access
Semantic Scholar
Abemaciclib in combination with therapies for patients with metastatic breast cancer: a phase 1b study
S. Tolaney, K. Jhaveri, T. Helsten, S. Puhalla +7 more
2025Frontiers in Oncology2 citations Open access
Semantic Scholar
Quantitative pre-treatment assessment of trastuzumab deruxtecan (T-DXd) antibody target (HER2) and payload target (topoisomerase 1, Topo1) to predict outcomes in metastatic breast cancer (MBC).
P. Tarantino, S. Kim, M. Hughes, Ashka Patel +16 more
2025Journal of Clinical Oncology2 citations
Semantic Scholar
ELEGANT: Elacestrant versus standard endocrine therapy (ET) in women and men with node-positive, estrogen receptor-positive (ER+), HER2-negative (HER2-), early breast cancer (eBC) with high risk of recurrence in a global, multicenter, randomized, open-label phase 3 study.
A. Bardia, V. Kaklamani, J. O'Shaughnessy, P. Schmid +14 more
2025Journal of Clinical Oncology2 citations Open access
Semantic Scholar
Germline determinants of pneumonitis in patients with cancer treated with antibody drug conjugates.
E. Yekeduz, E. Saad, M. Machaalani, Berkay Şímșek +16 more
2025Journal of Clinical Oncology2 citations Open access
Semantic Scholar
Elacestrant (Ela) combinations with ribociclib (Ribo) and everolimus (Eve) in patients (pts) with ER+/HER2- locally advanced or metastatic breast cancer (mBC): Update from ELEVATE, a phase (Ph) 1b/2, open-label, umbrella study.
H. Rugo, S. Tolaney, N. Chan, E. Hamilton +13 more
2025Journal of Clinical Oncology2 citations Open access
Semantic Scholar
DATO-Base: A phase II study of DATOpotamab deruxtecan for patients with breast cancer brain metastases or leptomeningeal disease.
P. Tarantino, Tian-Yu Li, Clare Strickland, M. DeMeo +11 more
2025Journal of Clinical Oncology2 citations
Semantic Scholar
Circulating tumor DNA and late recurrence in high-risk, hormone receptor-positive, HER2-negative breast cancer: An updated analysis of the CHiRP study.
T. Yoo, H. Heiling, K. Santos, M. Lipsyc-Sharf +12 more
2025Journal of Clinical Oncology1 citations Open access
Semantic Scholar
Abstract P4-08-09: Phase 3, Randomized, Open-label TroFuse-010 Study of Sacituzumab Tirumotecan (sac-TMT) Alone & W/ Pembrolizumab vs. Treatment of Physician’s Choice Chemotherapy in Patients With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer
S. Tolaney, P. D'Amico, Li-Yi Jia, K. Hirshfield +1 more
2025Clinical Cancer Research1 citations
Semantic Scholar
Cell-free circulating chromatin profiling for epigenomic characterization of mechanisms of response and resistance to sacituzumab govitecan in breast cancer.
A. Garrido-Castro, A. Gorthi, S. Kim, A. D'ippolito +16 more
2025Journal of Clinical Oncology1 citations Open access
Semantic Scholar
Abstract P4-03-19: Plasma-based prediction of prognosis, receptor status and organ involvement among patients receiving antibody-drug conjugates for metastatic breast cancer
P. Tarantino, Morganti, R. Vega, Francisco Pardo +28 more
2025Clinical Cancer Research1 citations
Semantic Scholar
Improving infusion therapy management in metastatic breast cancer: Real-world pilot study of a new pharmacy resource.
R. Mahtani, A. Bardia, S. Tolaney, Carolyn Oxencis +6 more
2025Journal of Clinical Oncology1 citations
Semantic Scholar
Assessing the impact of scalp cooling in patients receiving trastuzumab deruxtecan for metastatic breast cancer.
Elahe Salehi, X. Chu, E. Mayer, S. Singer +13 more
2025Journal of Clinical Oncology1 citations Open access
Semantic Scholar
Use of baseline plasma circulating tumor DNA (ctDNA) to predict duration of endocrine therapy (ET) and CDK4/6 inhibitor (CDK4/6i) therapy (tx) and to analyze intrinsic vs acquired endocrine resistance.
P. De Placido, M. Hughes, C. Weipert, S. Sammons +15 more
2025Journal of Clinical Oncology1 citations
Semantic Scholar
88MO Trastuzumab deruxtecan (T-DXd) + pertuzumab (P) vs taxane + trastuzumab + pertuzumab (THP) for first-line (1L) treatment of Asian patients (pts) with HER2+ advanced/metastatic breast cancer (a/mBC): A DESTINY-Breast09 analysis
Z. Jiang, Y. Park, M. Toi, S. Tolaney +11 more
2025Annals of Oncology1 citations
Semantic Scholar
Genomic alterations (GAs) associated with durability of benefit from trastuzumab deruxtecan (T-DXd), trastuzumab emtansine (T-DM1) and sacituzumab govitecan (SG) in metastatic breast cancer (MBC).
T. O'Meara, J. Quintanilha, P. Tarantino, D. Abravanel +4 more
2025Journal of Clinical Oncology1 citations
Semantic Scholar
Abstract PS9-08: Ultra-sensitive detection of circulating tumor DNA (ctDNA) in patients (pts) undergoing neoadjuvant endocrine therapy for hormone receptor-positive (HR+) early breast cancer (BC)
A. Grinshpun, D. Dustin, M. Cai, M. Hughes +8 more
2025Clinical Cancer Research1 citations
Semantic Scholar
Abstract P3-01-25: Molecular and immunological characterization of HER2-low, HER2 ultra-low, and HER2-null male breast cancer
D. Trapani, S. Deshmukh, Sharon Wu, J. Xiu +9 more
2025Clinical Cancer Research1 citations
Semantic Scholar
AXALAP: Phase Ib study of axatilimab in combination with olaparib in BRCA1/2 and PALB2 -associated metastatic HER2-negative breast cancer (BC).
F. Lynce, Adela Rodriguez Hernandez, S. Yadav, Ryan Buehler +10 more
2025Journal of Clinical Oncology1 citations Open access
Semantic Scholar
Abstract CT256: EmpowHER-303: A phase 3 study of zanidatamab vs trastuzumab with physician’s choice of chemotherapy in patients with HER2+ metastatic breast cancer whose disease progressed on trastuzumab deruxtecan
S. Tolaney, J. Cortés, E. Hamilton, H. Iwata +20 more
2025Cancer Research1 citations
Semantic Scholar
Abstract P1-09-28: Sociodemographic Experiences in Treatment (Tx) Patterns and Survival Outcomes in Women With Metastatic Triple-Negative Breast Cancer (mTNBC) in the United States (US): role of disparities
S. Tolaney, L. Spring, Y. Abdou, I. Ntalla +5 more
2025Clinical Cancer Research1 citations
Semantic Scholar
Abstract P5-10-07: Longitudinal survey on supportive care needs and coping strategies in women with recurrent/metastatic breast cancer
T. Sella, Shoshana M. Rosenberg, Alyssa R. Martin, M. Hughes +5 more
2025Clinical Cancer Research1 citations
Semantic Scholar
Abstract LB1-02: MARGOT/TBCRC052: A randomized phase II trial comparing neoadjuvant paclitaxel/margetuximab/pertuzumab (TMP) vs paclitaxel/trastuzumab/pertuzumab (THP) in patients (pts) with stage II-III HER2+ breast cancer
A. Waks, H. Heiling, P. Pohlmann, M. Rimawi +28 more
2025Clinical Cancer Research1 citations
Semantic Scholar
Abstract P2-11-04: Incidence and pattern of central nervous system recurrence in TNBC according to response after neoadjuvant treatments
T. Grinda, Alyssa R. Martin, M. Hughes, C. Corti +5 more
2025Clinical Cancer Research1 citations
Semantic Scholar
Association of immune, proliferation gene signatures and stromal tumor infiltrating lymphocytes (sTILs) with outcomes in patients with stage I triple-negative breast cancer (TNBC).
P. Tarantino, Tian-Yu Li, L. Paré, Esther Sanfeliu Torres +16 more
2025Journal of Clinical Oncology1 citations
Semantic Scholar
A phase 1b study of Plk1 inhibitor onvansertib in combination with paclitaxel in metastatic triple-negative breast cancer (mTNBC) patients.
A. Giordano, Q. Jin, E. Wrabel, Raechel Davis +16 more
2025Journal of Clinical Oncology1 citations Open access
Semantic Scholar
34P AI-based assessment of tumor-infiltrating Lymphocytes (TILs) in metastatic triple-negative breast cancer (mTNBC) treated with carboplatin +/- nivolumab
I. Schlam, K. Abduljabbar, H. Heiling, H. Yan +16 more
2026ESMO Open0 citations Open access
Semantic Scholar
A meta-analysis of single agent and dual immune checkpoint inhibitors in metastatic triple negative breast cancer
P. Zavras, Hugo R. Lara-Martinez, Qi Nie, Ming Li +11 more
2026npj Breast Cancer0 citations Open access
Semantic Scholar
Trastuzumab deruxtecan plus pertuzumab in first-line HER2-positive advanced/metastatic breast cancer
S. Tolaney, S. Loibl
2026Translational Cancer Research0 citations Open access
Semantic Scholar
Patient-reported outcomes from the TBCRC 022 study of neratinib and ado-trastuzumab emtansine for HER2-positive breast cancer brain metastases
T. Grinda, H. Heiling, N. Tayob, K. Smith +24 more
2026Breast0 citations Open access
Semantic Scholar
Giredestrant plus Everolimus in Advanced Breast Cancer
E. Mayer, S. Tolaney, Miguel Martín, G. Vidal +19 more
2026New England Journal of Medicine0 citations Open access
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

N. Tayob×17
Invite
N. Tayob — researcher profile on SciRah
N. Lin×16
Invite
N. Lin — researcher profile on SciRah
P. Tarantino×8
Invite
P. Tarantino — researcher profile on SciRah
H. Rugo×8
Invite
H. Rugo — researcher profile on SciRah

×8

Invite

S. Sammons — researcher profile on SciRah

Invite

M. Hughes — researcher profile on SciRah

Invite

E. Winer — researcher profile on SciRah

G. Curigliano×6

Invite

G. Curigliano — researcher profile on SciRah

Invite

P. Schmid — researcher profile on SciRah

A. Garrido-Castro×5

Invite

A. Garrido-Castro — researcher profile on SciRah

Invite

A. Bardia — researcher profile on SciRah

Invite

A. Waks — researcher profile on SciRah